FGF22

Across TCGA pan-cancer cohorts, FGF22 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FGF22 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FGF22 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FGF22 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where FGF22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.907	0.716	.014	10	view →
LUAD	DFS	Tertile	All	0.529	1.000	.023	9	view →
CCRCC	DFS	Median	II,III,IV	0.575	0.878	.021	4	view →
LSCC	DFS	Median	II,III,IV	0.508	0.830	.017	4	view →
GBM	DFS	Quartile	All	0.814	0.592	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FGF22–HNSC (DFS)

Open the HNSC breakdown →